Institute for Clinical & Economic Review Releases Evidence Report on Treatments for Sickle Cell Disease
March 13, 2020
March 13, 2020
BOSTON, Massachusetts, March 13 -- The Institute for Clinical and Economic Review issued the following announcement:
The Institute for Clinical and Economic Review (ICER) released an Evidence Report assessing the comparative clinical effectiveness and value of treatments for sickle cell disease, including crizanlizumab (Adakveo(R), Novartis), voxelotor (Oxbryta(TM), Global Blood Therapeutics), and L-glutamine (Endari(R), Emmaus Life Sciences).
"Patients and familie . . .
The Institute for Clinical and Economic Review (ICER) released an Evidence Report assessing the comparative clinical effectiveness and value of treatments for sickle cell disease, including crizanlizumab (Adakveo(R), Novartis), voxelotor (Oxbryta(TM), Global Blood Therapeutics), and L-glutamine (Endari(R), Emmaus Life Sciences).
"Patients and familie . . .